No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CGEN240517P2500
- 0.65
- 0.000.00%
15min DelayTrading Apr 22 09:53 ET
0.00High0.00Low
0.00Open0.65Pre Close0 Volume10 Open Interest2.50Strike Price0.00Turnover359.35%IV0.73%PremiumMay 17, 2024Expiry Date0.44Intrinsic Value100Multiplier4DDays to Expiry0.21Time Value100Contract SizeAmericanOptions Type-0.6314Delta0.4667Gamma4.85Leverage Ratio-0.0347Theta-0.0002Rho-3.06Eff Leverage0.0008Vega
Intraday
- 5D
- 1D
News
Merck Discontinues Testing of Experimental Skin Cancer Combo Therapy
Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024
Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Investors Don't See Light At End Of Compugen Ltd.'s (NASDAQ:CGEN) Tunnel And Push Stock Down 26%
Compugen Ltd. (NASDAQ:CGEN) shareholders that were waiting for something to happen have been dealt a blow with a 26% share price drop in the last month.
Express News | Compugen Reports Publication Of Paper In Cancer Immunology Research Demonstrating Therapeutic Potential Of COM503
Compugen to Participate in Two Upcoming Investor Conferences
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Truist Financial Reaffirms Their Buy Rating on Compugen (CGEN)
Comments
The market anticipates a decline in future revenue, possibly explaining the suppressed P/S. This weak revenue outlook could continue to pressure shares, making it hard to maintain current prices. Shareholders accept the low P/S, expecting future revenue may not bring pleasant surprises.
$Compugen(CGEN.US$ fk entered very early! now no option to hold at lesast 2 week or more !
$Compugen(CGEN.US$ 👀looks good i n game 🎲
Michelle Mahler's appointment as Chief Medical Officer is a positive step for Compugen, thanks to her vast clinical development experience. Her leadership in the COM503 Phase 1 study and future role in advancing COM701, COM902, and COM503 are anticipated to significantly boost the company's clinical development strategy.
Read more